In addition, patients with estrogen receptor (ER)-negative and/or human epidermal growth factor receptor-2 (HER2)-positive breast cancer who achieve pathological complete response (pCR) following NAC have better clinical outcomes2,3. This evidence concerns the gene ERBB2 and breast cancer.